Welcome to CSNpharm! For Research Use Only!
CDK
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN16440 | Wogonin | 632-85-9 | Wogonin acts as an inhibitor of COX2 with IC50 of 46 M without affecting COX-1 and inhibits the NF-B pathway-mediated iNOs induction. Wogonin can be isolated from the root of scutellaria baicalensis georgi. |
| CSN24147 | Voruciclib | 1000023-04-0 | Voruciclib is a protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with potential antineoplastic activity. |
| CSN25265 | Trilaciclib | 1374743-00-6 | Trilaciclib is an inhibitor of CDK4 and CDK6 with IC50s of 1 nM and 4 nM, respectively. |
| CSN22094 | Trilaciclib HCl | 1977495-97-8 | Trilaciclib hydrochloride is a CDK4/6 inhibitor with IC50s of 1 nM and 4 nM for CDK4 and CDK6, respectively. |
| CSN24801 | TP353 | 1253799-29-9 | TP353 is a CDK7 inhibitor. |
| CSN24290 | THZ532 | 1702809-22-0 | THZ532 is an inactive enantiomer of THZ531. |
| CSN16220 | THZ1 | 1604810-83-4 | THZ1 is a selective and potent covalent CDK7 inhibitor with IC50 binding affinity of 32 nM and inhibits Jurkat cells proliferation with IC50 of 50 nM |
| CSN22287 | THAL-SNS-032 | 2139287-33-3 | THAL-SNS-032 is a selective PROTAC, consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN), targeting on CDK9. |
| CSN26130 | TAK-931 | 1330782-76-7 | TAK-931 is an oral CDC7-selective inhibitor as a candidate clinical anticancer drug. It induced S phase delay and replication stress. |
| CSN25349 | SR-4853 | 2387704-62-1 | SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 with IC50 of 99 nM, Kd of 98 nM for CDK12 and Kd of 4.9 nM for CDK13. It acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death. |
| CSN23869 | Senexin B | 1449228-40-3 | Senexin B is a potent and selective CDK8/19 inhibitor. |
| CSN23674 | SEL120-34A HCl | 1609452-30-3 | SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity. |
| CSN11862 | Roscovitine | 186692-46-6 | Roscovitine is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM and shows little effect on CDK4/6. |
| CSN19761 | Roniciclib | 1223498-69-8 | Roniciclib is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity, selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation. |
| CSN22310 | CDK9-PROTAC | 2118356-96-8 | PROTAC CDK9 Degrader-1 is a CRBN-recruiting PROTAC selectively targeting on CDK9, consist of a CDK9 ligand (aminopyrazole analog) linked to a CRBN E3 ligand thalidomide. |
| CSN25543 | PNU 112455A | 21886-12-4 | PNU112455A HCl is an ATP site competetive inhibitor of CDK2 and CDK5. The Km for binding to the ATP site of CDK2 and CDK5 is 3.6 and 3.3 mM, respectively. |
| CSN16230 | PHA-767491 | 845714-00-3 | PHA-767491 is a potent ATP-competitive dual Cdc7Cdk9 inhibitor with IC50 values of 1034 nM and also an inhibitor of NRF2 |
| CSN24146 | PF-06873600 | 2185857-97-8 | PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6 respectively. PF-06873600 has potential antineoplastic activity. |
| CSN18553 | NVP-LCQ195 | 902156-99-4 | NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM. |
| CSN27187 | NVP-2 | 1263373-43-8 | NVP-2 is a potent and selective ATP-competitive CDK9 inhibitor with IC50 value of 0.5nM. |
| CSN25261 | NSC-95397 | 93718-83-3 | NSC 95397 is irreversible Cdc25 dual specificity phosphatase inhibitor with Ki values of 32, 96, and 40 nM for Cdc25A, Cdc25B, and Cdc25C, respectively. |
| CSN23650 | ML 315 | 1440251-53-5 | ML 315 is inhibitor of Clk and DYRK kinases with IC50s of 68, 68 and 231 nM for Clk1, Clk4 and Clk2, 282 and 1156 nM for Dyrk1A and Dyrk1B. |
| CSN23665 | ML 315 HCl | 2172559-91-8 | ML 315 HCl is inhibitor of Clk and DYRK kinases with IC50s of 68, 68 and 231 nM for Clk1, Clk4 and Clk2, 282 and 1156 nM for Dyrk1A and Dyrk1B. |
| CSN24194 | MC180295 | 2237942-08-2 | MC180295 is a selective CDK9 inhibitor with IC50 values of 5nM, 112nM, 138nM, 159nM, 186nM, 233nM, 367nM, 399nM, 555nM and 712nM for CDK9-Cyclin T1, CDK4-Cyclin D, CDK1-Cyclin B, cdk5-p35, cdk5-p25, cdk2-cyclin A, cdk2-cyclin E, CDK3-Cyclin E, CDK7-CycH/MAT1 and cdk6-cyclin D3. |
| CSN26115 | JSH-150 | 2247481-21-4 | JSH-150 is a highly selective CDK9 kinase inhibitor with IC50 value of 1nM. It dose-dependently inhibited the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrested the cell cycle and induced the apoptosis in the leukemia cells. |
| CSN22284 | JH-XI-10-02 | 2209085-22-1 | JH-XI-10-02 is a PROTAC selectively targeting on CDK8 with IC50 value of 159nM, and is consist of a warhead target on CDK8 (a Cortistatin A derivate) linked to CRBN ligand Pomalidomide. |
| CSN11014 | Flavopiridol | 146426-40-6 | Flavopiridol is a pan CDK inhibitor with IC50 values of 30nM, 40nM, 20-40nM, 60nM, 875nM and 20nM for CDK1, 2, 4, 6, 7, 9, respectively |
| CSN11015 | Flavopiridol HCl | 131740-09-5 | Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. |
| CSN24779 | EHT 5372 | 1425945-60-3 | EHT 5372 is a strong inhibitor of DYRK’s family kinases, with IC50s of 0.22, 0.28 nM for DYRK1A and DYRK1B, respectively. |
| CSN18431 | Dinaciclib | 779353-01-4 | Dinaciclib is a potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively. |
| CSN10712 | Cucurbitacin E | 18444-66-1 | Cucurbitacin E is a widely available plant-derived natural product, making it a useful tool to study actin dynamics in cells and actin-based processes such as cytokinesis. |
| CSN22367 | CDK8-IN-3 | 1884500-15-5 | CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7. |
| CSN26129 | CDK2 inhibitor 73 | 2079895-42-2 | CDK2 inhibitor 73 is a selective CDK2 inhibitor with IC50 value of 44nM. |
| CSN23778 | cc671 | 1618658-88-0 | CC-671 is a selective inhibitor of TTK (Mps1) and CLK2 with IC50s of 5 nM and 3 nM, respectively. |
| CSN23969 | BSJ-03-123 | 2361493-16-3 | BSJ-03-123 is a PROTAC selectively targeting on CDK6, consist of a warhead palbociclib (a CDK inhibitor) linked to a CRBN ligand pomalidomide. |
| CSN25245 | BS-194 | 1092443-55-4 | BS-194 is a selective and potent CDK inhibitor with IC50 values of 3, 30, 30, 250, and 90nM for CDK2, CDK1, CDK5, CDK7, and CDK9, respectively. |
| CSN17259 | Briciclib | 865783-99-9 | Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells |
| CSN20540 | BRD6989 | 642008-81-9 | BRD6989 selectively upregulates IL-10 through inhibiting CDK8 activity. |
| CSN24819 | Bohemine | 189232-42-6 | Bohemine is a potent and selective, cell-permeable, cyclin-dependent kinase (CDK) inhibitor with IC50 = 1 µM. Bohemine is structurally similar to Olomoucine and Roscovitine. |
| CSN25300 | BI-1347 | 2163056-91-3 | BI-1347 is a potent CDK8 inhibitor with an IC50 of 1.1 nM. |
| CSN21503 | AZD5438 | 602306-29-6 | AZD5438 is a potent inhibitor of CDK129 with IC50 of 16620 nM |
| CSN24735 | AZD4573 | 2057509-72-3 | AZD4573 is a potent and selective CDK9 inhibitor with with nanomolar. |
| CSN21194 | Atuveciclib Racemate | 1414943-88-6 | Atuveciclib Racemate is the racemate form of Atuveciclib. |
| CSN25869 | Atuveciclib | 1414943-94-4 | Atuveciclib is an orally available and selective PTEFb/CDK9 inhibitor for the treatment of cancer. |
| CSN27194 | (±)-BAY-1251152 | 1610358-53-6 | (±)-BAY-1251152 is a racemic mixture form of BAY-1251152. BAY 1143572 is the first selective, orally available PTEFb/CDK9 inhibitor that entered clinical development with IC50 value of 3nM. |
| CSN26940 | (-)-((2-((5-Fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)amino)pyridin-4-yl)methyl)(imino)(methyl)-l6-sulfanone | 1610358-59-2 | (-)-BAY-1251152 is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor. |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
